Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
limosilactobacillus fermentum SLAM216 extracellular vesicles
- Development stage
- Preclinical
- Lead developer
- Seoul National University
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
Limosilactobacillus fermentum SLAM216 extracellular vesicles (LF216EV) is an experimental, probiotic-derived biologic. It consists of nano-sized extracellular vesicles from the Limosilactobacillus fermentum SLAM 216 bacterial strain, which contain a complex mixture of proteins, enzymes, nucleic acids, and lipids (including linoleic, oleic, palmitic, sebacic, and stearic acids). [1] LF216EV functions by modulating the gut microbiota and serotonin metabolism pathways. It has been shown to target immune regulatory genes (such as TSLP, TNFα, IL-6, IL-1β) in cell models. [2] This mechanism, operating through the gut-skin axis, leads to increased serotonin synthesis and has shown potential in preclinical mouse models for treating atopic dermatitis and associated psychiatric symptoms like anxiety and depression. [1, 2] It is currently considered an academic research compound with developers at institutions like Seoul National University and the Korea Food Research Institute. [2, 5]
- Other names
- Limosilactobacillus fermentum SLAM 216-derived extracellular vesicles
Beyond the preview
Go deeper on limosilactobacillus fermentum SLAM216 extracellular vesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on limosilactobacillus fermentum SLAM216 extracellular vesicles.